NBIX

NEUROCRINE BIOSCIENCES INC

Healthcare | Large Cap

$2.13

EPS Forecast

$1,067

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Neurocrine Biosciences 2Q 2026: INGREZZA Keeps the Lights On, Guidance Gets a Booster

Ticker: NBIX. In the latest quarterly update, NBIX emphasizes revenue strength and a growing pipeline, with references to EPS, EPS consensus, earnings surprise, and a revenue forecast embedded in the narrative—though the exhibit focuses on top-line momentum rather than per-share details. The stock story hinges on the durability of INGREZZA’s cash generation and the company’s ability to turn an expanding pipeline into sustained earnings power.

Key quarterly highlights

  • Total revenue: $959 million for the quarter, up 39% year over year.
  • INGREZZA net product sales: $716 million in Q2 2026, up from $624 million in Q2 2025 (YoY growth of 15%).
  • CRENESSITY (crinecerfont) net product sales: $184 million in Q2 2026, vs $53 million in Q2 2025.
  • Strategic move: Acquisition of Soleno Therapeutics completed in May 2026.
  • 2026 net sales guidance: Raised to a range of $2.825 billion to $2.875 billion.
  • Pipeline catalysts: Phase 3 readouts anticipated in 2027 for osavampator (major depressive disorder) and direclidine (schizophrenia).

What the numbers imply for Neurocrine and peers

The quarter reads as a confirmation that a core product can keep revenue wheels turning while the company leans into a broader, risk-managed growth strategy. INGREZZA remains the engine—it’s not just churning out cash but also funding an expanding late-stage and discovery portfolio. The 39% quarterly gain signals strong demand dynamics, and the 15% YoY growth in INGREZZA sales shows a durable core franchise rather than a one-off spike.

CRENESSITY’s ascent from a modest base to $184 million in net product sales signals optionality in the portfolio beyond the flagship medicine. It’s a textbook example of a company layering incremental franchises to dilute idiosyncratic risk in a biotech-heavy growth trajectory. The Soleno acquisition, completed in May 2026, adds another vector to the growth story, potentially improving scalability and cross-sell opportunities as the pipeline expands.

From a capital-allocation perspective, the raised revenue forecast suggests management believes the revenue trajectory is sustainable enough to support longer-term value creation. Investors will be watching two things on the EPS side: whether an earnings-per-share figure emerges clearly in future updates and how the company balances reinvestment in late-stage assets with shareholder-friendly moves. In the present data dump, EPS remains unreported in this excerpt, so the EPS consensus remains a forward-looking question mark—one that could swing sentiment if the next print reveals a tighter margin or a more pronounced impact from the Soleno integration.

Strategic takeaways for NBIX and sector peers

Neurocrine’s story hinges on product durability and pipeline optionality. INGREZZA’s continued revenue contribution helps fund late-stage programs while maintaining a credible revenue forecast for 2026. The Soleno deal, now closed, adds optionality that investors tend to reward when it shows up in the right balance sheet, not just in a press release. For sector peers, the lesson is simple: a strong core product can provide a platform for disciplined expansion—whether through acquisitions, new indications, or faster progression of Phase 3 assets—without sacrificing margin discipline during the expansion cycle.

The 2027 milestones—osavampator in major depressive disorder and direclidine in schizophrenia—are the next big test. If the markets trust the execution, you could see a re-rating of NBIX on the back of multiple revenue ladders rather than a single rung. If the reads come in softer-than-expected, it could reignite the old pharma-earnings debate about dependency on a lead program versus a diversified pipeline.

Risks, caveats, and the sector lens

As with any growth-at-scale pharma story, the usual suspects apply: pricing pressure, competitive dynamics, and the risk that a Phase 3 result disappoints. The Soleno acquisition introduces integration risk and potential disruption to the financial profile if cost structures don’t align with the expanded portfolio. Still, the revenue beat and raised guidance reduce the immediate risk of a downward earnings surprise scenario in the near term, at least on top-line terms. Sector peers will be watching how NBIX translates pipeline ambition into earnings momentum, particularly when balancing R&D intensity with return on invested capital.

Note: This summary reflects the disclosed figures in Neurocrine Biosciences’ press release and Exhibit 99.1 (Q2 2026). All figures are unaudited and in millions, unless noted otherwise.